Elsevier

Maturitas

Volume 19, Issue 2, August 1994, Pages 125-131
Maturitas

Hormone replacement therapy in perimenopausal women with a low dose oral contraceptive preparation: Effects on bone mineral density and metabolism

https://doi.org/10.1016/0378-5122(94)90062-0Get rights and content

Abstract

In a 2-year longitudinal, calcium-controlled study we evaluated bone density and metabolism in perimenopausal women with initial ovarian failure, and the effects of hormone replacement with a low dose oral contraceptive preparation (OC). In perimenopausal oligomenorrhoic women (n = 16) a significant (P < 0.01) increase in cycle length and plasma FSH levels as well as a parallel decrease in plasma estradiol levels (P < 0.01) were evident. In this group, despite the calcium supplementation (500 mg/day), a significant (P < 0.001) increase in the biochemical markers of bone remodelling paralleled a significant (P < 0.001) decrease (-3.4% after 24 months) in bone density. Conversely, in premenopausal oligomenorrhoic women treated with a low dose oral contraceptive (OC) formulation (30 mcg ethinyl estradiol plus 75 mcg gestodene, n = 16), bone markers showed a significant (P < 0.01) decrease, that paralleled a slight but significant (P < 0.01) increase (+1.71%) in bone density. These data suggest that premenopausal administration of OC can prevent the acceleration of bone turn-over and reverse the decrease in bone density that follows the premenopausal impairment of ovarian function.

References (30)

  • BL Riggs et al.

    Differential changes in bone mineral density of the appendicular and axial skeleton with ageing

    J Clin Invest

    (1981)
  • L Nilas et al.

    Age related bone loss in women evaluated by a single and dual photon technique

    Bone Min

    (1988)
  • L Nilas et al.

    The pathophysiology of peri-and postmenopausal bone loss

    Br J Obstet Gynaecol

    (1989)
  • M Gambacciani et al.

    Evaluation of bone density in premenopausal women

  • M Gambacciani et al.

    Premenopausal bone loss in oligomenorrhoic women: a longitudinal study

    Maturitas

    (1994)
  • Cited by (60)

    • The combined oral contraceptive pill- recent developments, risks and benefits

      2014, Best Practice and Research: Clinical Obstetrics and Gynaecology
    • Impact of oral contraceptive on bone metabolism

      2013, Best Practice and Research: Clinical Endocrinology and Metabolism
      Citation Excerpt :

      A review paper1 of 13 studies in women using low-dose oral contraceptives reported a positive effect of COC on BMD in 9 studies and 4 studies did not show an association. It is during the late perimenopausal years that the bone effect of COC appears the most relevant in preventing the activation of bone metabolism and the decrease in BMD.2–8 In perimenopausal oligomenorrheic women, the progressive ovarian failure is associated with a decreased production of estradiol which activates bone turnover with a subsequent increase in bone loss.

    • Hormonal contraception and bone metabolism: A systematic review

      2012, Contraception
      Citation Excerpt :

      Randomized controlled studies are needed to confirm these data. Gambacciani et al. [149–152] performed four randomized prospective studies evaluating BMD at the hip, heel, spine and radius of perimenopausal women treated with COCs. In each study, women experiencing oligomenorrhea were randomized to COCs (20 mcg EE/150 mg desogestrel or 30 mcg EE/75 mg gestodene) or calcium (500 mg/day).

    • Use of Contraceptives for Older Women

      2007, Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, Third Edition
    View all citing articles on Scopus
    View full text